EA200870555A1 - Слитые белки, их применение и способы их получения - Google Patents

Слитые белки, их применение и способы их получения

Info

Publication number
EA200870555A1
EA200870555A1 EA200870555A EA200870555A EA200870555A1 EA 200870555 A1 EA200870555 A1 EA 200870555A1 EA 200870555 A EA200870555 A EA 200870555A EA 200870555 A EA200870555 A EA 200870555A EA 200870555 A1 EA200870555 A1 EA 200870555A1
Authority
EA
Eurasian Patent Office
Prior art keywords
proteins
amino acids
peptide
present
peptide linker
Prior art date
Application number
EA200870555A
Other languages
English (en)
Inventor
Йорам Рейтер
Рой Ной
Кфир Овед
Original Assignee
Тева Фармасьютикал Индастриз, Лтд.
Текнион Рисерч Энд Дивелопмент Фаундейшн Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Тева Фармасьютикал Индастриз, Лтд., Текнион Рисерч Энд Дивелопмент Фаундейшн Лтд. filed Critical Тева Фармасьютикал Индастриз, Лтд.
Publication of EA200870555A1 publication Critical patent/EA200870555A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Abstract

Настоящее изобретение относится к слитому белку, содержащему последовательные аминокислоты, которые, начиная с аминоконца белка, соответствуют последовательным аминокислотам, присутствующим в (i) пептиде цитомегаловируса человека, рестриктированному по МНС, (ii) первом пептидном линкере, (iii) β-2-микроглобулине человека, (iv) втором пептидном линкере, (v) цепи HLA-A2 молекулы МНС человека класса I, (vi) третьем пептидном линкере, (vii) вариабельной области тяжелой цепи фрагмента scFv антитела и (viii) вариабельной области легкой цепи такого фрагмента scFv, причем последовательные аминокислоты, соответствующие (vii) и (viii), непосредственно связаны друг с другом пептидной связью или с помощью последовательных аминокислот, соответствующих четвертому пептидному линкеру, и антитело, из которого происходит фрагмент scFv, специфически связывается с мезотелином. Настоящее изобретение относится к конструкции нуклеиновых кислот, кодирующих указанные слитые белки, способам продуцирования указанных слитых белов, композиции и применению указанных слитых белов.
EA200870555A 2006-05-19 2007-05-17 Слитые белки, их применение и способы их получения EA200870555A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80179806P 2006-05-19 2006-05-19
PCT/US2007/011953 WO2007136778A2 (en) 2006-05-19 2007-05-17 Fusion proteins, uses thereof and processes for producing same

Publications (1)

Publication Number Publication Date
EA200870555A1 true EA200870555A1 (ru) 2009-04-28

Family

ID=38723866

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200870555A EA200870555A1 (ru) 2006-05-19 2007-05-17 Слитые белки, их применение и способы их получения

Country Status (16)

Country Link
US (4) US7977457B2 (ru)
EP (1) EP2024507B1 (ru)
JP (1) JP5225266B2 (ru)
KR (1) KR101442209B1 (ru)
CN (1) CN101448951B (ru)
AU (1) AU2007254167B2 (ru)
BR (1) BRPI0712716A2 (ru)
CA (1) CA2652538C (ru)
EA (1) EA200870555A1 (ru)
ES (1) ES2549128T3 (ru)
HK (1) HK1122335A1 (ru)
IL (1) IL195191A (ru)
MX (1) MX2008014722A (ru)
NO (1) NO342211B1 (ru)
WO (1) WO2007136778A2 (ru)
ZA (1) ZA200810677B (ru)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040191260A1 (en) 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
IL151860A0 (en) * 2000-03-27 2003-04-10 Technion Res & Dev Foundation Single chain class i major histocompatibility complexes, constructs encoding same and methods of generating same
US8022190B2 (en) * 2001-06-19 2011-09-20 Technion Research & Development Foundation Ltd. Immuno-molecules containing viral proteins, compositions thereof and methods of using
CN101448951B (zh) * 2006-05-19 2013-04-10 泰华制药工业有限公司 融合蛋白、其用途以及制备方法
US7947274B2 (en) * 2007-01-04 2011-05-24 Humabs, LLC. Human cytomegalovirus neutralising antibodies and use thereof
GB0700133D0 (en) 2007-01-04 2007-02-14 Humabs Llc Human cytomegalovirus neutralising antibodies and use thereof
EP2361930A3 (en) 2007-03-26 2011-10-26 Dako Denmark A/S Multimers of MHC-peptide complexes and uses thereof in Borrelia infectious diseases
EP3023436A1 (en) 2007-07-03 2016-05-25 Dako Denmark A/S Improved methods for generation, labeling and use of mhc multimers
WO2009039854A2 (en) 2007-09-27 2009-04-02 Dako Denmark A/S Mhc multimers in tuberculosis diagnostics, vaccine and therapeutics
US8647840B2 (en) 2007-12-11 2014-02-11 The Scripps Research Institute In vivo unnatural amino acid expression in the methylotrophic yeast Pichia pastoris
US10968269B1 (en) 2008-02-28 2021-04-06 Agilent Technologies, Inc. MHC multimers in borrelia diagnostics and disease
PE20141433A1 (es) 2008-07-16 2014-10-19 Inst Research In Biomedicine Anticuerpos neutralizantes de citomegalovirus humano
US10722562B2 (en) 2008-07-23 2020-07-28 Immudex Aps Combinatorial analysis and repair
GB0817244D0 (en) 2008-09-20 2008-10-29 Univ Cardiff Use of a protein kinase inhibitor to detect immune cells, such as T cells
US10369204B2 (en) 2008-10-02 2019-08-06 Dako Denmark A/S Molecular vaccines for infectious disease
WO2010068278A2 (en) 2008-12-10 2010-06-17 The Scripps Research Institute Production of carrier-peptide conjugates using chemically reactive unnatural amino acids
ES2949159T3 (es) 2010-05-06 2023-09-26 Novartis Ag Composiciones y métodos de uso para anticuerpos terapéuticos de proteína 6 relacionada con lipoproteínas de baja densidad (LRP6)
KR20130066631A (ko) 2010-05-06 2013-06-20 노파르티스 아게 치료적 저밀도 지단백질-관련 단백질 ６ （ｌｒｐ６） 다가 항체에 대한 조성물 및 사용 방법
MX345519B (es) 2010-12-20 2017-02-01 Genentech Inc Anticuerpos anti-mesotelina e inmunoconjugados.
WO2012097313A2 (en) 2011-01-14 2012-07-19 The Regents Of The University Of California Therapeutic antibodies against ror-1 protein and methods for use of same
AU2012222833B2 (en) 2011-03-03 2017-03-16 Zymeworks Inc. Multivalent heteromultimer scaffold design and constructs
CN103561771B (zh) * 2011-03-17 2019-01-04 伯明翰大学 重新定向的免疫治疗
SG195077A1 (en) * 2011-06-22 2013-12-30 Hoffmann La Roche Removal of target cells by circulating virus-specific cytotoxic t-cells using mhc class i comprising complexes
WO2013040557A2 (en) 2011-09-16 2013-03-21 The Trustees Of The University Of Pennsylvania Rna engineered t cells for the treatment of cancer
EP2773669B1 (en) 2011-11-04 2018-03-28 Novartis AG Low density lipoprotein-related protein 6 (lrp6) - half life extender constructs
WO2013184790A1 (en) * 2012-06-05 2013-12-12 Eaton Corporation Interchangeable flow restricting orifice for clamshell coupler
WO2014012082A2 (en) 2012-07-13 2014-01-16 Zymeworks Inc. Multivalent heteromultimer scaffold design an constructs
KR20150088881A (ko) * 2012-11-30 2015-08-03 로슈 글리카트 아게 암세포 표적화된 mhc 클래스 i 포함 다중기능 단백질을 사용하는 순환 바이러스-특이적 세포독성 t-세포에 의한 암세포의 제거
CN109324190A (zh) 2012-12-11 2019-02-12 艾伯特叶史瓦大学爱因斯坦医学院 高通量受体:配体鉴定方法
JP6475167B2 (ja) 2012-12-21 2019-02-27 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ジスルフィド結合した多価ｍｈｃクラスｉを含む多機能タンパク質
CA2936352A1 (en) * 2014-01-21 2015-07-30 Albert Einstein College Of Medicine, Inc. Cellular platform for rapid and comprehensive t-cell immunomonitoring
WO2015165480A1 (en) 2014-04-30 2015-11-05 Institute For Research In Biomedicine Human cytomegalovirus vaccine compositions and method of producing the same
US10457716B2 (en) * 2014-08-06 2019-10-29 University Of Notre Dame Du Lac Protein folding and methods of using same
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
JP2019522466A (ja) 2016-05-18 2019-08-15 アルバート アインシュタイン カレッジ オブ メディシン，インコーポレイティド 変異ｐｄ−ｌ１ポリペプチド、ｔ細胞調節多量体ポリペプチド、及びそれらの使用方法
CA3019005A1 (en) 2016-05-18 2017-11-23 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
CA3043630A1 (en) 2016-12-22 2018-06-28 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
CN107663239A (zh) * 2016-12-28 2018-02-06 天津天锐生物科技有限公司 一种识别hla‑a2/nlvpmvatv的单域抗体
EP3565829A4 (en) 2017-01-09 2021-01-27 Cue Biopharma, Inc. MULTIMER POLYPEPTIDES T-LYMPHOCYTE MODULATORS AND THEIR METHODS OF USE
CN111010875B (zh) 2017-03-15 2024-04-05 库尔生物制药有限公司 用于调节免疫应答的方法
EP3737689A4 (en) 2018-01-09 2021-12-01 Cue Biopharma, Inc. MULTIMERIC T CELL-MODULATING POLYPEPTIDES AND METHOD OF USING THEREOF
EP3755711A4 (en) * 2018-02-20 2021-11-24 Technion Research & Development Foundation Limited IMMUNOTHERAPEUTIC COMPOSITION FOR THE TREATMENT OF CANCER
CA3100576A1 (en) * 2018-06-20 2019-12-26 Danmarks Tekniske Universitet Scaffolds with stabilized mhc molecules for immune-cell manipulation
US20220047710A1 (en) * 2018-09-12 2022-02-17 Washington University Single chain constructs
WO2020243315A1 (en) * 2019-05-29 2020-12-03 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
JP2023526723A (ja) 2020-05-12 2023-06-23 キュー バイオファーマ， インコーポレイテッド 多量体ｔ細胞調節性ポリペプチド及びその使用方法
WO2023126544A1 (en) * 2022-01-03 2023-07-06 Aarhus Universitet Proteinaceous compound for generating specific cytotoxic t-cell effect

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) * 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) * 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) * 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) * 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) * 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) * 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) * 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) * 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US6416738B1 (en) * 1973-12-07 2002-07-09 Neorx Corporation Pretargeting methods and compounds
JPS6054684A (ja) 1983-09-05 1985-03-29 Teijin Ltd 新規ｄνａ及びハイブリツドｄνａ
IL82104A0 (en) 1986-04-08 1987-10-30 Usa Recombinant vaccinia virus expressing human retrovirus genes and method for producing htlb-iii envelope proteins
GB8608850D0 (en) 1986-04-11 1986-05-14 Diatech Ltd Packaging system
US5591829A (en) * 1987-05-29 1997-01-07 Matsushita; Shuzo Antibodies modified with toxic substance
US5260422A (en) 1988-06-23 1993-11-09 Anergen, Inc. MHC conjugates useful in ameliorating autoimmunity
US5194425A (en) 1988-06-23 1993-03-16 Anergen, Inc. Mhc-mediated toxic conjugates useful in ameliorating autoimmunity
US5468481A (en) 1988-06-23 1995-11-21 Amergen, Inc. MHC class II-peptide conjugates useful in ameliorating autoimmunity
DE3825615A1 (de) 1988-07-28 1990-02-01 Behringwerke Ag Antigenkonstrukte von "major histocompatibility complex" klasse i antigenen mit spezifischen traegermolekuelen, ihre herstellung und verwendung
US6291160B1 (en) * 1989-05-16 2001-09-18 Scripps Research Institute Method for producing polymers having a preselected activity
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US6153408A (en) 1991-11-15 2000-11-28 Institut Pasteur And Institut National De La Sante Et De La Recherche Medicale Altered major histocompatibility complex (MHC) determinant and methods of using the determinant
US6011146A (en) 1991-11-15 2000-01-04 Institut Pasteur Altered major histocompatibility complex (MHC) determinant and methods of using the determinant
US20030129191A1 (en) * 1992-12-23 2003-07-10 Neorx Corporation Pretargeting methods and compounds
US5837477A (en) 1993-01-15 1998-11-17 The United States Of America As Represented By The Department Of Health And Human Services T cell receptor ligands and methods of using same
US5695928A (en) * 1993-12-10 1997-12-09 Novartis Corporation Rapid immunoassay for detection of antibodies or antigens incorporating simultaneous sample extraction and immunogenic reaction
US5820866A (en) 1994-03-04 1998-10-13 National Jewish Center For Immunology And Respiratory Medicine Product and process for T cell regulation
ES2152424T5 (es) 1994-07-29 2010-07-05 Sunol Molecular Corporation Complejos del mhc y usos de los mismos.
GB9415492D0 (en) * 1994-08-01 1994-09-21 Celltech Ltd Biological products
US5635363A (en) 1995-02-28 1997-06-03 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for the detection, quantitation and purification of antigen-specific T cells
WO1997024446A2 (en) 1995-12-29 1997-07-10 Chiron Corporation Gene delivery vehicle-targeting ligands
US5869270A (en) 1996-01-31 1999-02-09 Sunol Molecular Corporation Single chain MHC complexes and uses thereof
CA2250166A1 (en) 1996-03-28 1997-10-02 The Johns Hopkins University Soluble divalent and multivalent heterodimeric analogs of proteins
US6140113A (en) 1996-03-28 2000-10-31 The Johns Hopkins University Polynucleotides encoding molecular complexes which modify immune responses
US6211342B1 (en) 1996-07-18 2001-04-03 Children's Hospital Medical Center Multivalent MHC complex peptide fusion protein complex for stimulating specific T cell function
US6562345B1 (en) * 1996-11-12 2003-05-13 City Of Hope Immuno-reactive peptide CTL epitopes of human cytomegalovirus
US6248564B1 (en) 1997-08-29 2001-06-19 Harvard University Mutant MHC class I molecules
ATE423789T1 (de) 1997-09-16 2009-03-15 Univ Oregon Health & Science Rekombinante mhc-moleküle welche nützlich sind für die manipulation von antigen-spezifischen t- zellen
US6232445B1 (en) 1997-10-29 2001-05-15 Sunol Molecular Corporation Soluble MHC complexes and methods of use thereof
ATE317437T1 (de) * 1997-12-01 2006-02-15 Us Gov Health & Human Serv Antikörper, sowie fv moleküle, und immunkonjugate mit hoher bindungsaffinität für mesothelin und methoden für deren verwendung
GB2339782A (en) 1998-06-05 2000-02-09 Philip Michael Savage Chimeric protein complexes comprising HLA class I antigens
WO2000064946A2 (en) * 1999-04-28 2000-11-02 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting vegf
US6680209B1 (en) * 1999-12-06 2004-01-20 Biosite, Incorporated Human antibodies as diagnostic reagents
US20040191260A1 (en) * 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
IL151860A0 (en) 2000-03-27 2003-04-10 Technion Res & Dev Foundation Single chain class i major histocompatibility complexes, constructs encoding same and methods of generating same
AU2001255326B2 (en) 2000-04-12 2005-12-15 University Of Rochester Targeted vaccine delivery systems
WO2001090198A1 (en) 2000-05-24 2001-11-29 Ludwig Institute For Cancer Research Multicomponent conjugates which bind to target molecules and stimulate cell lysis
GB0026812D0 (en) 2000-11-02 2000-12-20 Isis Innovation Cancer therapy
US20030017134A1 (en) 2001-06-19 2003-01-23 Technion Research And Development Foundation Ltd. Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer
US8022190B2 (en) 2001-06-19 2011-09-20 Technion Research & Development Foundation Ltd. Immuno-molecules containing viral proteins, compositions thereof and methods of using
GB0115071D0 (en) 2001-06-20 2001-08-15 Avidex Ltd Substances
US7362707B2 (en) 2001-07-23 2008-04-22 Acme Packet, Inc. System and method for determining flow quality statistics for real-time transport protocol data flows
US6992176B2 (en) * 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
EP1485075A4 (en) * 2002-02-20 2006-04-26 Dyax Corp MHC-PEPTIDE COMPLEX BINDING LIGANDS
US7632866B2 (en) * 2002-10-21 2009-12-15 Ramot At Tel Aviv University Derivatives of N-phenylanthranilic acid and 2-benzimidazolone as potassium channel and/or neuron activity modulators
CN101448951B (zh) 2006-05-19 2013-04-10 泰华制药工业有限公司 融合蛋白、其用途以及制备方法

Also Published As

Publication number Publication date
US20080014208A1 (en) 2008-01-17
KR20090048397A (ko) 2009-05-13
EP2024507A4 (en) 2009-09-23
MX2008014722A (es) 2011-04-15
NO20085272L (no) 2009-02-18
IL195191A0 (en) 2009-08-03
CA2652538C (en) 2016-06-28
IL195191A (en) 2017-01-31
ES2549128T3 (es) 2015-10-23
US20150152161A1 (en) 2015-06-04
KR101442209B1 (ko) 2014-11-18
NO342211B1 (no) 2018-04-16
JP5225266B2 (ja) 2013-07-03
JP2009537175A (ja) 2009-10-29
US20110150874A1 (en) 2011-06-23
BRPI0712716A2 (pt) 2012-05-22
WO2007136778A3 (en) 2008-03-27
CN101448951A (zh) 2009-06-03
US7977457B2 (en) 2011-07-12
AU2007254167A1 (en) 2007-11-29
HK1122335A1 (en) 2009-05-15
ZA200810677B (en) 2010-03-31
EP2024507B1 (en) 2015-07-22
US20170211076A1 (en) 2017-07-27
CA2652538A1 (en) 2007-11-29
WO2007136778A2 (en) 2007-11-29
CN101448951B (zh) 2013-04-10
EP2024507A2 (en) 2009-02-18
AU2007254167B2 (en) 2012-11-15

Similar Documents

Publication Publication Date Title
EA200870555A1 (ru) Слитые белки, их применение и способы их получения
AR077088A1 (es) Proteinas biespecificas de union a antigeno
US20200031898A1 (en) Peptide mimotopes of claudin 18.2 and uses thereof
CY1118709T1 (el) Αντιγονικα πεπτιδια του παραγοντα διεγερσης αποικιων των κοκκινοκυτταρων (gm-csf) και αντισωματα για ton gm-csf
EA201490262A1 (ru) Модифицированные белки и пептиды
PE20190514A1 (es) Proteinas de union de tipo anticuerpo biespecificas que se unen especificamente a cd3 y cd123
PE20091269A1 (es) Moleculas de union al receptor ox40 humano
RS53175B (en) IL-4 AND / OR IL-13 BINDING ANTIBODIES AND THEIR USES
JP2014158485A5 (ru)
CY1115939T1 (el) Il-31 μονοκλωνικα αντισωματα και μεθοδοι χρησης
RU2013110875A (ru) БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА, СОДЕРЖАЩИЕ СТАБИЛИЗИРОВАННЫЙ ДИСУЛЬФИДОМ ФРАГМЕНТ Fv
RU2015152077A (ru) Тримерные антигенсвязывающие молекулы
EA201190132A1 (ru) Гуманизированные антитела, связывающиеся с cd19, и их применение
TW200732350A (en) Methods for generating monovalent IgG
EA201400568A1 (ru) Альбуминсвязывающие антитела и их связывающие фрагменты
IS2786B (is) Prótín sem bindast viðtaka Nogo
RU2015153109A (ru) Содержащие суперспираль и/или привязку белковые комплексы и их применения
RU2012131671A (ru) Способ полипептидной модификации для очистки полипептидных мультимеров
WO2006113546A3 (en) Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
RU2015111708A (ru) Способ получения и отбора молекул, включающих по меньшей мере две различные группировки и их применение
NZ596865A (en) Single-chain multivalent binding proteins with effector function
RU2015129640A (ru) Связанные дисульфидом мультивалентные многофункциональные белки, содержащие молекулы гкгс класса 1
JP2020180133A (ja) 変異した骨格を有する結合ポリペプチド
JP2019502694A (ja) 二特異性抗体基幹
JP2018515453A5 (ru)